Filing Flows › Puma Biotechnology (PBYI) › Q3 2026 › vs Q3 2025
Puma Biotechnology (PBYI) Q3 2026 vs Q3 2025 (year over year)
Puma Biotechnology's revenue rose $625K (+1%) from $54.5M in Q3 2025 to $55.1M in Q3 2026. The biggest changes: Product revenue, net +$2.2M (+4%); Royalty revenue −$1.6M (-62%). Operating margin 9.6% against 17.6% (-8.0 pts).
Puma Biotechnology, Q3 2026: revenue $55.1M (+1% year over year), operating margin 9.6%, net earnings $6.0M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Operating margin | 9.6% | 17.6% | -8.0 pts |
| Net margin | 10.9% | 16.2% | -5.3 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Product revenue, net | $54.1M | $51.9M | $2.2M | +4% |
| Royalty revenue | $1.0M | $2.6M | −$1.6M | -62% |
| Revenue | $55.1M | $54.5M | $625K | +1% |
| Other income, net | $900K | −$330K | $1.2M | — |
| Operating profit | $5.3M | $9.6M | −$4.3M | -45% |
| Costs & expenses | $49.8M | $44.9M | $4.9M | +11% |
| Pre-tax earnings | $6.2M | $9.2M | −$3.0M | -33% |
| Cost of revenue | $15.2M | $12.2M | $3.0M | +25% |
| Research & development | $18.3M | $15.9M | $2.4M | +15% |
| SG&A | $16.3M | $16.8M | −$517K | -3% |
| Net earnings | $6.0M | $8.8M | −$2.8M | -32% |
| Income tax | $200K | $399K | −$199K | -50% |
Questions
How much did Puma Biotechnology's revenue grow year over year in Q3 2026?
Puma Biotechnology's revenue rose $625K (+1%) from $54.5M in Q3 2025 to $55.1M in Q3 2026.
What drove Puma Biotechnology's revenue change in Q3 2026?
Product revenue, net +$2.2M (+4%); Royalty revenue −$1.6M (-62%).